Loading...
•
Jun 30, 2025
Sana Q2 2025 Earnings Report
Sana Q2 2025 results showed a widened net loss due in large part to an asset impairment charge and continued R&D investment.
Key Takeaways
Sana Biotechnology reported a Q2 2025 net loss of $93.8 million driven by impairment charges, while reducing operating expenses with non-GAAP results highlighting continued investment in R&D and cash runway into 2H 2026.
Net loss for the quarter was $93,800,000 compared to prior year Q2.
Research and development expenses declined during the quarter.
General and administrative expenses were lower compared with last year.
Cash, cash equivalents and marketable securities totaled $72,700,000 at quarter end.
Forward Guidance
Management noted clinical progress and strengthened balance sheet post quarter with financing expected to support operations into the second half of 2026.
Positive Outlook
- Positive clinical momentum in type 1 diabetes pipeline with UP421 data.
- Proceeds of approximately $105 million raised after quarter end strengthen cash runway.
- FDA INTERACT feedback supports SC451 development path.
- Lower operating expenses help manage cash burn.
- Expected progress in filing INDs in 2026.
Challenges Ahead
- Net loss widened due to one-time impairment charges.
- Revenue remains nil as clinical stage company.
- High cash burn continues to necessitate financing.
- Dependence on future capital markets.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...